NYSE - Delayed Quote USD

Pfizer Inc. (PFE)

25.39 -0.03 (-0.12%)
At close: April 18 at 4:00 PM EDT
25.36 -0.03 (-0.12%)
After hours: April 18 at 7:59 PM EDT
Loading Chart for PFE
DELL
  • Previous Close 25.42
  • Open 25.35
  • Bid --
  • Ask --
  • Day's Range 25.23 - 25.46
  • 52 Week Range 25.23 - 40.37
  • Volume 35,461,604
  • Avg. Volume 42,898,575
  • Market Cap (intraday) 143.772B
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) 68.62
  • EPS (TTM) 0.37
  • Earnings Date May 1, 2024
  • Forward Dividend & Yield 1.68 (6.62%)
  • Ex-Dividend Date Jan 25, 2024
  • 1y Target Est 29.28

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

88,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PFE

Performance Overview: PFE

Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PFE
10.48%
S&P 500
5.06%

1-Year Return

PFE
35.17%
S&P 500
20.71%

3-Year Return

PFE
25.87%
S&P 500
19.73%

5-Year Return

PFE
18.25%
S&P 500
72.77%

Compare To: PFE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PFE

Valuation Measures

As of 4/19/2024
  • Market Cap

    143.77B

  • Enterprise Value

    201.93B

  • Trailing P/E

    68.62

  • Forward P/E

    11.45

  • PEG Ratio (5yr expected)

    0.25

  • Price/Sales (ttm)

    2.45

  • Price/Book (mrq)

    1.62

  • Enterprise Value/Revenue

    3.45

  • Enterprise Value/EBITDA

    21.13

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.62%

  • Return on Assets (ttm)

    1.55%

  • Return on Equity (ttm)

    2.35%

  • Revenue (ttm)

    58.5B

  • Net Income Avi to Common (ttm)

    2.13B

  • Diluted EPS (ttm)

    0.37

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12.69B

  • Total Debt/Equity (mrq)

    84.37%

  • Levered Free Cash Flow (ttm)

    1.02B

Research Analysis: PFE

Analyst Price Targets

24.48
29.28 Average
25.39 Current
42.37 High
 

Fair Value

Undervalued
% Return
25.39 Current
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Research Reports: PFE

  • Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

    In this edition, European interest-rate cuts on the horizon; firm opportunities among drug and biopharma firms; and reports Tesla's affordable vehicle will be canceled; and Lazard, PVH, and Genmab.

     
  • Large Cap US Pick List - April 2024

    This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.

     
  • Technical Assessment: Neutral in the Intermediate-Term

    Was that a case of quarter-end buying by institutions? Over the last 50 minutes of the trading session on Wednesday, the S&P 500 (SPX) took off like a rocket, surging 30 points and finishing 0.9% higher on the day and at another all-time high. But the biggest winners on the day were small-caps, with the Russell 2000 (IWM) surging 2.2% and the S&P 600 (SML) spiking 2.4%. The IWM is breaking out of a more-than two-year base and closed at its highest level since December 2021.

     
  • Analyst Report: Pfizer Inc.

    Pfizer is a leading developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.

    Rating
    Neutral
    Price Target
     

People Also Watch